1. Home
  2. BRSP vs ANNX Comparison

BRSP vs ANNX Comparison

Compare BRSP & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BrightSpire Capital Inc.

BRSP

BrightSpire Capital Inc.

HOLD

Current Price

$5.35

Market Cap

738.7M

Sector

Real Estate

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.48

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRSP
ANNX
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
738.7M
812.7M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
BRSP
ANNX
Price
$5.35
$5.48
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$6.50
$16.50
AVG Volume (30 Days)
2.2M
4.4M
Earning Date
04-28-2026
05-11-2026
Dividend Yield
11.03%
N/A
EPS Growth
75.24
N/A
EPS
0.03
N/A
Revenue
$330,587,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17.54
$16,320.74
P/E Ratio
$177.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.87
$2.03
52 Week High
$6.17
$7.18

Technical Indicators

Market Signals
Indicator
BRSP
ANNX
Relative Strength Index (RSI) 43.09 47.94
Support Level $5.24 $4.66
Resistance Level $5.46 $5.65
Average True Range (ATR) 0.11 0.55
MACD 0.01 -0.04
Stochastic Oscillator 38.96 32.10

Price Performance

Historical Comparison
BRSP
ANNX

About BRSP BrightSpire Capital Inc.

BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: